Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Asscociates
mi
from
Phoenix, AZ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Asscociates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northern AZ Hematology and Oncology Assoc
mi
from
Sedona, AZ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northern AZ Hematology and Oncology Assoc
mi
from
Sedona, AZ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern Connecticut Oncology-Hematology Associates
mi
from
Torrington, CT
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern Connecticut Oncology-Hematology Associates
mi
from
Torrington, CT
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Melbourne Internal Medicine Associates
mi
from
Melbourne, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Melbourne Internal Medicine Associates
mi
from
Melbourne, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Institute
mi
from
New Port Richey, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Institute
mi
from
New Port Richey, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates of IL
mi
from
Chicago, IL
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates of IL
mi
from
Chicago, IL
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Central Indiana Cancer Center
mi
from
Indianapolis, IN
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Central Indiana Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kansas City Cancer-Southwest
mi
from
Overland Park, KA
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kansas City Cancer-Southwest
mi
from
Overland Park, KA
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
NH Oncology-Hematology, PA
mi
from
Hooksett, NH
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Associates of NNJ, PA
mi
from
Morristown, NJ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Associates of NNJ, PA
mi
from
Morristown, NJ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Summit Medical Group
mi
from
Summit, NJ
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Summit Medical Group
mi
from
Summit, NJ
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC
mi
from
Rexford, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC
mi
from
Rexford, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Raleigh Hematology Oncology Clinic
mi
from
Cary, NC
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Raleigh Hematology Oncology Clinic
mi
from
Cary, NC
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Center
mi
from
Eugene, OR
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Center
mi
from
Eugene, OR
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of the Carolinas, Seneca
mi
from
Seneca, SC
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of the Carolinas, Seneca
mi
from
Seneca, SC
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Texas Cancer Center
mi
from
Dallas, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Texas Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Center - Denton
mi
from
Denton, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Center - Denton
mi
from
Denton, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
Fredericksburg, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
Fredericksburg, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Houston, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Longview Cancer Center
mi
from
Longview, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Longview Cancer Center
mi
from
Longview, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Allison Cancer Center
mi
from
Midland, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
HOAST - New Braunfels
mi
from
New Braunfels, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
HOAST - New Braunfels
mi
from
New Braunfels, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Texas Cancer Center
mi
from
Odessa, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Texas Cancer Center
mi
from
Odessa, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials